Trend: shift in marketing
Pharmaceutical companies continued to pour money into advertising that targets consumers and physicians during the first half of 1998, according to new findings from IMS Health.
Pharmaceutical companies continued to pour money into advertising that targets consumers and physicians during the first half of 1998, according to new findings from IMS Health, Plymouth Meeting, PA.
For that time period, spending on advertising aimed at physicians reached $2.5 billion, or nearly 80% of total promotional spending. Spending on direct-to-consumer advertising reached $631 million.
Primarily, companies invested their dollars in television marketing. Top spenders poured $306 million - more than 48% of the total amount spent on consumer advertising - into commercials. They spent $277 million on magazine advertisements and $50.7 million on newspaper advertisements.
Last year, total spending on television commercials was a mere $302 million, or 28.5% of the industry's total investment of $1.06 billion). Spending on magazine advertisements, meanwhile, exceeded $644 million, or 60.7% of the total.
Heavier investment in new means of promotion does not mean that companies are scaling back on face-to-face selling, however. According to IMS Health, the pharmaceutical industry spent $1.8 billion - nearly 65% of total spending - on face-to-face selling with office-based physicians during the first half of 1998. "This represents a 25% increase over the same period a year ago," IMS Health noted. PR
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
